| Zhihong Wang,Hong Ji,Qiong Qiu,Jianlan Wang. Role of serum lactate dehydrogenase levels in evaluating efficacy of interventional therapy for hepatocellular carcinoma. Oncol Transl Med, 2018, 4: 238-241. |
| 血清乳酸脱氢酶在肝癌介入治疗疗效评估中的意义 |
| Role of serum lactate dehydrogenase levels in evaluating efficacy of interventional therapy for hepatocellular carcinoma |
| Received:September 12, 2018 Revised:January 14, 2019 |
| DOI：10.1007/s10330-018-0299-9 |
| 中文关键词: 原发性肝癌；乳酸脱氢酶；介入治疗；预后 |
| 英文关键词: primary hepatocellular carcinoma (HCC); lactate dehydrogenase (LDH); interventional therapy; prognosis |
| 基金项目: |
| Author Name | Affiliation | E-mail | | Zhihong Wang* | Huangzhou District People's Hospital, Huanggang, Hubei | 402924257@qq.com | | Hong Ji | Huangzhou District People's Hospital, Huanggang, Hubei | | | Qiong Qiu | Huangzhou District People's Hospital, Huanggang, Hubei | | | Jianlan Wang | Huangzhou District People's Hospital, Huanggang, Hubei | |
|
| Hits: 9082 |
| Download times: 10392 |
| 中文摘要: |
| 摘要
目的：探讨血清乳酸脱氢酶（LDH）在原发性肝癌肝动脉化疗栓塞术（TACE）疗效评估中的临床价值。
方法：选取2013年6月至2017年12月在我院行TACE的52例肝癌患者，根据治疗前LDH水平，分为对照组（LDH≤450 U/L）和观察组（LDH>450 U/L），每组各26例。根据治疗前后LDH血清水平的变化对患者进行分类，升高组22例，降低组30例。回顾性分析LDH与两组TACE治疗疗效的关系。
结果：对照组与观察组在临床特征（性别，中位年龄，性能状态ECOG，分期系统）之间没有统计学差异。对照组患者治疗有效率为57.7%，而观察组患者为42.3%（P >0.05）。观察组患者的1年生存率为53.8%，对照组患者的1年生存率为84.6%（p <0.05）。
结论：血清LDH可能具有评估HCC患者TACE治疗疗效的临床价值。 |
| 英文摘要: |
| Objective?The aim of the study was to investigate the role of serum lactate dehydrogenase (LDH) levels in evaluating the efficacy of transcatheter arterial chemoembolization (TACE) for primary liver cancer.
Methods?A total of 52 patients with liver cancer admitted in our hospital (Huangzhou District People’s Hospital, Huanggang, China) from June 2015 to December 2017 were selected and divided into control group (LDH of ≤ 450 U/L, n = 26) and observation group (LDH of > 450 U/L, n = 26), based on the pretreatment level of LDH. Based on the changes in serum LDH levels before and after treatment, patients were classified into two groups: LDH increased group (22 cases) and LDH decreased group (30 cases). The relationship between LDH levels and efficacy of TACE treatment was analyzed in the four groups retrospectively.
Results?No significant difference was seen in the clinical characteristics (gender, median age, performance status Eastern Cooperative Oncology Group, and staging system) between the control and observation groups. The efficacy rate in the control group was 57.7%, whereas that in the observation group was 42.3% (P > 0.05). The 1-year survival rate in the observation group was 53.8% and that in the control group was 84.6% (P < 0.05).
Conclusion?Serum LDH levels may be of clinical value in evaluating the efficacy of TACE in patients with hepatocellular carcinoma. |
|
View Full Text
Download reader HTML全文 |
| Close |
|
|
|